---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-029992"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:55:23.075210+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dogwood Therapeutics Q4 loss $3.8M; Halneuron Phase 2b >50% enrolled, top-line Q3 2026

## Summary
- Net loss Q4 2025 $3.8M ($0.26/share) vs $8.2M ($6.29) in Q4 2024; full year loss $35.5M ($7.13).
- Cash $6.5M at Dec 31, 2025; Jan 2026 financing raised $11.4M net to fund through Phase 2b readout.
- Halneuron CINP Phase 2b >50% enrolled; interim analysis showed separation from placebo; top-line expected Q3 2026.
- R&D expenses FY 2025 $21.8M (up from $3.5M) due to $12.0M SP16 license fee and clinical trial costs.
- G&A expenses fell to $6.1M from $8.7M due to lower nonrecurring transaction costs.

## SEC filing metadata
- accession: 0001104659-26-029992
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000110465926029992/0001104659-26-029992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000110465926029992/dwtx-20260318x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-029992
- JSON: https://secwatch.observer/filing/0001104659-26-029992.json
- Plain text: https://secwatch.observer/filing/0001104659-26-029992.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.